Bär & Karrer advise Eppendorf in its investment in BigOmics Analytics 

Eppendorf, a life science company that develops, produces and distributes products and services for the use in laboratories worldwide, made an investment in BigOmics Analytics, a Swiss biodata analytics start-up company, as part of their Pre-Series A financing round. 

The additional funding brings the total amount raised by BigOmics Analytics to CHF 2.7 million, which will be used to further develop BigOmics’ platforms, to expand its team and to grow its presence in the market. 

BigOmics was founded in 2018 as a spin-off of the cancer research institute IOR and the Artificial Intelligence institute IDSIA and graduated from the US-based Alchemist Accelerator. Current investors include TiVentures, ADM Partners, Century Oak Capital, Champion Hill Ventures, Acequia Capital, as well as business angels Raul Vejar, Mark Jalabert and Nathan Kaiser (from the Swiss ICT Investor Club network). 

Bär & Karrer acted as legal advisor to Eppendorf in this transaction. The team was led by partners Christoph Neeracher and Raphael Annasohn and further included associate Adrian Zampieri and junior associate Lazar Lepir (all m&a) as well as partner Thomas Stoltz (Notarial Services).